Lupin gets USFDA nod to market generic drug

The company has received approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA), Vigabatrin for Oral Solution USP (500 mg), Lupin said in a statement.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/31QdulX
via IFTTT